NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) arising in nonalcoholic fatty liver disease (NAFLD) may not be suitable for systemic therapy due to metabolic syndrome-related diseases. Recent trials did not show a survival benefit of radioembolization (RE) compared to sorafenib in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Liver Cancer
Main Authors: Schotten, Clemens, Bechmann, Lars P., Manka, Paul, Theysohn, Jens, Dechêne, Alexander, El Fouly, Amr, Barbato, Francesco, Neumann, Ursula, Radünz, Sonia, Sydor, Svenja, Heider, Dominik, Venerito, Marino, Canbay, Ali, Gerken, Guido, Herrmann, Ken, Wedemeyer, Heiner, Best, Jan
Format: Artigo
Jezik:Inglês
Izdano: S. Karger AG 2019
Teme:
Original Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883476/
https://ncbi.nlm.nih.gov/pubmed/31799206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000501484
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki